BD to invest $100 million in Nebraska to expand insulin syringe manufacturing
Investment will include new technology and manufacturing equipment
BD (Becton, Dickinson and Company) is investing $100 million in its Holdrege, Nebraska facility in the US to expand capacity for its insulin syringe manufacturing operations.
The investment will fund new technology and manufacturing equipment to expand capacity for BD insulin syringes.
The medical technology firm already produces more than two billion insulin syringes each year, which averages at more than 250,000 syringes every hour.
'About 40% of people with diabetes who inject insulin use syringes as part of their diabetes management regimen,' said Ken Miller, Worldwide President of Diabetes Care for BD.
'This investment will provide benefits to this diabetes population and underscores our commitment to supply high-quality, industry-leading insulin syringes to patients.'
BD began operations in Holdrege in 1966 in a 12,000 ft2 (1,115 m2) building with 66 staff.
The facility is now 350,000 ft2 (32,000 m2) and employs more than 650 people who manufacture 20 different BD products.
Across Nebraska, BD employs more than 2,500 people in four manufacturing facilities in Holdrege, Broken Bow and two in Columbus.